GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beta Drugs Ltd (NSE:BETA) » Definitions » Price-to-Owner-Earnings

Beta Drugs (NSE:BETA) Price-to-Owner-Earnings : 42.79 (As of Jun. 06, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Beta Drugs Price-to-Owner-Earnings?

As of today (2024-06-06), Beta Drugs's share price is ₹1190.00. Beta Drugs's Owner Earnings per Share (TTM) ended in Mar. 2024 was ₹27.81. It's Price-to-Owner-Earnings for today is 42.79.


The historical rank and industry rank for Beta Drugs's Price-to-Owner-Earnings or its related term are showing as below:

NSE:BETA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.89   Med: 51.1   Max: 382.35
Current: 43.23

During the past 12 years, the highest Price-to-Owner-Earnings of Beta Drugs was 382.35. The lowest was 13.89. And the median was 51.10.


NSE:BETA's Price-to-Owner-Earnings is ranked worse than
73.22% of 422 companies
in the Drug Manufacturers industry
Industry Median: 25.855 vs NSE:BETA: 43.23

As of today (2024-06-06), Beta Drugs's share price is ₹1190.00. Beta Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹37.90. Therefore, Beta Drugs's PE Ratio for today is 31.40.

As of today (2024-06-06), Beta Drugs's share price is ₹1190.00. Beta Drugs's EPS without NRI for the trailing twelve months (TTM) ended in was ₹37.90. Therefore, Beta Drugs's PE Ratio without NRI for today is 31.40.

During the past 12 years, Beta Drugs's highest PE Ratio without NRI was 52.47. The lowest was 4.57. And the median was 23.19.


Beta Drugs Price-to-Owner-Earnings Historical Data

The historical data trend for Beta Drugs's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beta Drugs Price-to-Owner-Earnings Chart

Beta Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.48 13.55 33.21 39.63 44.36

Beta Drugs Semi-Annual Data
Mar13 Mar14 Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.21 - 39.63 - 44.36

Competitive Comparison of Beta Drugs's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beta Drugs's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Beta Drugs's Price-to-Owner-Earnings falls into.



Beta Drugs Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Beta Drugs's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1190.00/27.81
=42.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beta Drugs  (NSE:BETA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Beta Drugs Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Beta Drugs's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Beta Drugs (NSE:BETA) Business Description

Traded in Other Exchanges
N/A
Address
SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports it to other countries of which key revenue is derived from the sales made in India.

Beta Drugs (NSE:BETA) Headlines

No Headlines